## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

wasnington,	D.C.	20548

TATEMENT	OF CHANGES	IN RENEEICIAL	OWNEDS

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

						JI SEI	Clion 30(11) 01	uie iii	vesum	ieni Ci	Uniparty Act of	1940								
Name and Address of Reporting Person*     VAGELOS P ROY			<u>R</u>	2. Issuer Name and Ticker or Trading Symbol REGENERON PHARMACEUTICALS, INC. [ REGN ]  5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner												ner				
(Last) 777 OLD	(Fii SAW MILI	rst) L RIVER ROAD	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 12/11/2019								X	X Officer (give title below) Other (specify below)  Chairman of the Board					
(Street)	OWN NY	Y	10591		4. 1	I. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable     X Form filed by One Reporting Person					cable Line)	
(City)	(St	ate)	(Zip)											Form filed by More than One Reporting Person						
		Ta	able I - N	lon-De	erivativ	ve S	ecurities	Acq	uired	d, Di	sposed of,	or Ben	eficia	ally O	wned					
1. Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Yea		2A. Deemed Execution Date, ar) if any (Month/Day/Year)		e,   T	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an			5)	5. Amount of Securities Beneficially Owned Follo	у	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Direct Indirect If	7. Nature of ndirect Beneficial Ownership			
								С	ode	v	Amount	(A) or (D)	Price		Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
Common S	Stock			12/1	2/2019			1	M <sup>(1)</sup>		107,655	A	\$21	.25	412,1	140		D		
Common S	Stock			12/1	2/2019			F <sup>(1)</sup> 55,813		55,813	D	\$377.16		356,327			D			
Common S	Stock			12/1	3/2019	2019			S <sup>(1)</sup>		632	D	\$373	.26 <sup>(2)</sup>	355,695			D		
Common S	Stock			12/1	3/2019	2019			S <sup>(1)</sup>		6,873	D	\$374	.79 <sup>(3)</sup>	348,822		2 D			
Common S	Stock			12/1	3/2019				S <sup>(1)</sup>		21,910	D	\$375	.55(4)	326,912		D			
Common S	Stock		12/13/		3/2019	2019			S <sup>(1)</sup>		13,060	D	\$376	.36 <sup>(5)</sup>	313,852			D		
Common Stock 12/13/2		3/2019				S <sup>(1)</sup>		5,732	D	\$377.47 <sup>(6)</sup>		308,120		D						
Common Stock 12/13/2		3/2019				S <sup>(1)</sup>		3,602	D	\$378.38 <sup>(7)</sup>		304,518		D						
Common S	Common Stock 12/13/2		3/2019	019			S <sup>(1)</sup>		33	D	\$379	\$379.14(8)		304,485		D				
Common Stock													2,326		I		3y 401(k) Plan			
Common S	Stock														144,897			I l	y CLAT	
Common Stock						$\perp$							83,652		552		Dy Spouse as Гrustee			
Common Stock													1,203			I f	oy trust for grandch <sup>(9)</sup>			
			Table II								oosed of, c				ned					
Derivative Conversion Date Execution Security or Exercise (Month/Day/Year) if any		3A. Deeme Execution if any (Month/Da	ed 4. Transa Code (		5. Number Derivative		nber of 6. Exitive (Note of (A) or sed of (D)		ate Exe	ercisable and	7. Title and An of Securities Underlying Derivative Sec (Instr. 3 and 4)		ount 8. Price of Derivativ Security		9. Numb derivativ Securitic Benefici Owned Followir	ve ies ially ng	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
					Code	v	(A) (D)		Date Exercisabl		Expiration Date	or Nu		ount mber shares	Reported Transactio (Instr. 4)					
Non- Qualified Stock Option (right to buy)	\$21.25	12/12/2019			M <sup>(1)</sup>		107	7,655	55 (10)		12/18/2019	Common Stock	107	,655	\$0.0	0		D		
Non- Qualified Stock Option (right to	\$372.46	12/11/2019					29,177	77		(11)	12/11/2029	Common Stock	29,	177	\$0.0	29,1	77	D		

## Explanation of Responses:

buy) Performance Stock Units

12/11/2019

9,086

Common

Stock

9,086

\$0.0

9,086

D

 $<sup>1.\</sup> Disposition/acquisition\ made\ pursuant\ to\ a\ plan\ intended\ to\ comply\ with\ Rule\ 10b5-1(c).$ 

<sup>2.</sup> Represents volume-weighted average price of sales of 632 shares of Company stock on December 13, 2019 at prices ranging from \$373.21 to \$373.51. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 13, 2019 at each separate price.

- 3. Represents volume-weighted average price of sales of 6,873 shares of Company stock on December 13, 2019 at prices ranging from \$374.22 to \$374.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 13, 2019 at each separate price.
- 4. Represents volume-weighted average price of sales of 21,910 shares of Company stock on December 13, 2019 at prices ranging from \$375.02 to \$375.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 13, 2019 at each separate price.
- 5. Represents volume-weighted average price of sales of 13,060 shares of Company stock on December 13, 2019 at prices ranging from \$376.00 to \$376.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 13, 2019 at each separate price.
- 6. Represents volume-weighted average price of sales of 5,732 shares of Company stock on December 13, 2019 at prices ranging from \$377.01 to \$377.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 13, 2019 at each separate price.
- 7. Represents volume-weighted average price of sales of 3,602 shares of Company stock on December 13, 2019 at prices ranging from \$378.07 to \$378.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 13, 2019 at each separate price.
- 8. Represents volume-weighted average price of sales of 33 shares of Company stock on December 13, 2019 at prices ranging from \$379.06 to \$379.19. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 13, 2019 at each separate price.
- 9. By a trust for the benefit of certain grandchildren of the reporting person, of which the reporting person and/or the spouse of the reporting person is trustee.
- 10. The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.
- 11. The stock option award vests in four equal annual installments, commencing one year after the date of grant.
- 12. Each performance-based restricted stock unit ("PSU") represents the contingent right to receive one share of the issuer's common stock at vesting. The amount reported reflects the maximum number of PSUs that may vest based upon the achievement of certain performance metrics related to total shareholder return over four-year and/or five-year performance periods ending on December 11, 2023 and December 11, 2024, respectively. Between 50% and 225% of the target number of PSUs (i.e., between 50% and 225% of 4,038 PSUs) may vest upon achievement of predetermined total shareholder return percentages derived from compound annual growth rates of 5% to 15% for the applicable performance period. If none of the performance metrics are achieved at the conclusion of the performance periods, the award expires.

By: Beverly Dubs, as attorney-

12/13/2019 in-fact For: P. Roy Vagelos

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.